Aptinyx Inc. Stock: price and insider trades · United States · SEC (Form 4)

About Aptinyx Inc.

Aptinyx Inc. (ticker: APTX) is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market in the United States. The company was incorporated in Delaware on June 24, 2015 and is headquartered in Evanston, Illinois. Aptinyx emerged from the scientific legacy of Naurex and has positioned itself around the discovery and development of proprietary synthetic small molecules for disorders of the brain and nervous system. That positioning places the company in a highly specialized and high-risk segment of healthcare, where scientific differentiation matters, but where timelines, capital needs, and regulatory execution are critical. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674365/000155837023005096/aptx-20221231x10k.htm?utm_source=openai)) Operationally, Aptinyx is best understood as a development-stage neuroscience biotech rather than a commercial pharmaceutical company. Its business model has centered on advancing product candidates through preclinical and clinical development in areas such as neuropathic pain, post-traumatic stress disorder, and cognitive disorders linked to neurological disease. This portfolio approach reflects a strategy of targeting serious conditions with substantial unmet medical need, where even a single clinical success could create meaningful value, but where the probability of failure remains material. ([aptinyx.com](https://www.aptinyx.com/ir-sub/press-releases/news-details/2020/Aptinyx-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option/default/?utm_source=openai)) From an equity analyst perspective, the key investment issue is that Aptinyx’s valuation is driven primarily by pipeline milestones rather than recurring sales. The company has publicly discussed programs including NYX-458 and NYX-783, which illustrates a research platform focused on central nervous system biology rather than a single-asset story. That can be attractive in terms of scientific optionality, but it also means the stock is typically highly sensitive to trial readouts, cash runway, financing conditions, and the regulatory path ahead. ([aptinyx.com](https://www.aptinyx.com/?utm_source=openai)) Geographically, Aptinyx’s footprint is concentrated in the United States, with corporate operations anchored in Evanston, near Chicago. Its current presence appears primarily U.S.-centered, while its eventual commercial opportunity, if any, would depend on regulatory approvals and the ability to expand beyond a domestic research base. For French, Belgian, and Swiss investors, this is therefore a classic U.S. biotech profile: scientifically promising, but with limited operating visibility until clinical and regulatory catalysts are cleared. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1674365/000155837023005096/aptx-20221231x10k.htm?utm_source=openai)) Recent public communications have mainly highlighted pipeline updates and phase 2 study results, reinforcing that the company remains in a development and capital-management phase rather than a revenue-generating commercial stage. In practical terms, Aptinyx should be viewed as a catalyst-driven NASDAQ-listed healthcare name in the United States, with business value tied to data, financing, and regulatory progress rather than near-term product sales. ([aptinyx.com](https://www.aptinyx.com/?utm_source=openai))